




社会责任报告

2020 SOCIAL RESPONSIBILITY REPORT



股票代码：600572



.....	3
.....	5
.....	6
.....	6
.....	7
.....	9
.....	10
“ ”	12
.....	13
“ ”	14
“ ” “ ”	15
.....	16
.....	17
“ ”	18
.....	19

.....20

.....21

.....24

.....25

.....27

.....29

.....32

.....33

.....34

.....35

.....36

.....39

.....42

.....44

OTC

66

"

“

”

30

9

“

"

44

22

关于
本报告

2020 12 31

2020

2020

2020 1 1

2020

>

<

“

”

FDA		
GMP		


2021 4 19

关于 康恩贝

一、公司概况

2004 4

600572



二、公司治理

2020 7
20%
13.33%

1

2

3

2020 7

11

4

^

三、企业文化



四、年度荣誉


2019	260	“ 2019
TOP100	”	
		2019
2019	“	”
2020	CHSESI	
		“ 70 70 .
”		
	2020	“ 2019
”	“ 2019	”
G60	“ G60	”
	2019	2019
“	”	2019
	“	”
2020	“	”
2020	“	”
2020-2021		
2020	2020 “	. ” ® & ®
2020 “	.	”
2020	2020 “	”

“ 2019-2020 ”

2019 “ ”

“ 2020 ” “ 2020 ”

2019



【共战“疫”】

2020

2020 1 20

“

”



一、担当以行

20 90 2003 “ ”

1800


2008 2030 70

1 22 “ ”

300 25 1000

1 24 1000

1 31 5 200



2 12
E 10000
“ ”
2 16 “

16 107
165
“ ”

75%
30
2020
1800


二、全力以“复”

1 26
2
1
“ ” 1 28
1 30
.....
X

“

σ

三、“疫”言“疫”行



2020 4 2

“

”

“

”

“

”

“

”

1

99

“

”

99



2

11 17

11 30

12 1

12 2

二、“十四五”规划绘蓝图 c P 2 P > ! I P A x c C

【焕新机】



2020 10 18 “

” 30


30 “

” 30




一、创新研发

1



2



3

1	1	1	1
2	4	2	

2020

2
6

2020	12	30	8
------	----	----	---

11

2020



7

2020



34

35

1001415

125

2020410310135


2020



9 27 Ŷ
Ŷ



11 9 Ŷ
Ŷ



10 13 Ŷ



5 27 Ŷ

二、药品质量

“	”	“	”
”			
/			
	CAPA	GMP	
。			
		↳ 1	
2 ≡			
2			
2		↳ →	。
0			
P		↔	6 ↑


三、安全生产

1

“ ”

$\hat{Y}$	BSCI				92	$\hat{Y}$	40	$\hat{Y}$ 201
	$\hat{Y}$	101	201		$\hat{Y}$	101	201	
$\hat{Y}$			101	201	$\hat{Y}$	BSCI		

2



3

“ ” “ ” “ 119 ” “ ”



4 “ 100 ” “

100 ”

2020 U&A 71% 35.9%

37.2% 78.2% 81.2%

5 “ ”

2020 U&A 18.1% 23.4% 30.3% 74.3%

6 “ ”

2020 U&A 19.79% 33.33% 25% 34.38% 57.89%

70.45%

7 “ ”

+

“ ”

“ ”

8 “ ”

9 2020 f



五、数字化建设

2020

1

2

2020

3



0A






4

5


2020







六、电商发力



【扛担当】



一、 股东回报

					17	
						2018 5 31
2017						
						www.sse.com.cn
	2018-040					
	2007	2010	2014			
2015			2020 12 31			19.90
				46.46%		



二、投资者关系管理

2020

5 8

2019

“ e ”

“ e ”

“ E ”

“

”

三、关爱员工

“ ”

1

9600

2

100%

100%

3

“ ”



4

2020

5

2017

1000

2020

148

270

2006


“

”

2006-

—

!



四、友好环境



3

“ ”

1

4

5



1

2020 6.5 “ ”

47.9% A “ ”

2019 A 2

2020

2019 A

2

2020


9 11 “ ”

3

A d



未来 展望





浙江康恩贝制药股份有限公司
浙江康恩贝药业股份有限公司
ZHEJIANG CONBA PHARMACEUTICAL CO., LTD.

568

0571-87774811

0571-87774722

310052

www.conbapharm.com

A

A

600572